Moritz Arndt University
Moritz Arndt University
News Article | February 21, 2017
Doctor at Basel University Hospital honored for clinical work on management of non-vitamin K dependent oral anticoagulants in acute stroke patients LEVERKUSEN, 21-Feb-2017 — /EuropaWire/ — The third winner of the Bayer Thrombosis Research Award has been chosen. The Scientific Committee of the Bayer Science & Education Foundation has awarded the EUR 30,000 prize to Dr. David Seiffge from the stroke research group in the Department of Neurology at Basel University Hospital in recognition of his clinically significant work on the management and safety of non-vitamin K dependent oral anticoagulants (NOACs) in patients with acute stroke. Seiffge and the research group showed that stroke patients in everyday clinical practice can be treated with NOAC as little as five days after the acute event. The bleeding risk was low at just 1.3 percent per 100 patient-years. They also showed that in acute stroke patients the results of determining the plasma concentration of rivaroxaban are available after just 30 minutes, which could open up new options for acute therapy. An international pilot study initiated by Dr. Seiffge and Prof. Stefan Engelter showed, for example, that thrombolysis could be performed successfully in selected stroke patients who had been receiving NOAC therapy. The Thrombosis Research Award has honored aspiring up-and-coming researchers for outstanding achievements in the field of pure and clinical research into thrombosis since 2013. It was established in 2011 by the Bayer scientists Dr. Frank Misselwitz, Dr. Dagmar Kubitza and Dr. Elizabeth Perzborn, who won the German Future Prize in 2009 for developing the anticoagulant Xarelto®. “Advances in science, both at universities and research institutes and in industry, are society’s investment in the future. We want to boost research and promote excellence,” said Kemal Malik, member of the Bayer AG Board of Management responsible for Innovation and Chairman of the Foundation. “Bayer is working to discover and develop new treatment options for diseases for which there is a high level of medical need. It is therefore also very important for us to support pioneering achievements both in medical research and clinical application. In addition, through its foundations and particularly through the awarding of this prize, Bayer wants to increase appreciation for top-level research and medical progress,” continued Malik. It was these considerations that led the three Bayer researchers to donate the EUR 250,000 prize money for winning the German Future Prize to establish this award for up-and-coming researchers. Bayer doubled this initial funding to EUR 500,000. Said Dr. Frank Misselwitz, prize sponsor and Head of the Cardiovascular and Coagulation Therapeutic Area in Bayer’s Clinical Research, “David Seiffge is a talented clinician whose work stands out from that of the many other nominees. His work on the patient safety of non-vitamin K dependent oral anticoagulants delivers findings that are significant for clinical practice. In view of his outstanding scientific work, Dr. Seiffge is most particularly deserving of this award.” With the exception of the prize sponsors themselves, the scientific judging panel for the new award is made up exclusively of experts from universities and hospitals all over Germany: Professor Michael Böhm (Saarland University Hospital), Professor Christoph Bode (Freiburg-im-Breisgau University Hospital), Professor Andreas Greinacher (Ernst Moritz Arndt University Hospital, Greifswald), Professor Edelgard Lindhoff-Last (CCB – Cardiovascular Center Bethanien, Frankfurt-am-Main) and Professor Bernhard Nieswandt (Rudolph Virchow Center at the University of Würzburg). The prize is awarded by the Bayer Science & Education Foundation. The overriding aims of this foundation are to recognize outstanding research achievements, promote scientific talent and support key natural science projects in schools. In terms of content, the focus of its sponsorship activities is on natural sciences and medicine. Outstanding research achievements are honored by the Foundation in alternate years with the Hansen Family Prize and the Otto Bayer Prize, both of which are endowed with EUR 75,000. Two prizes for aspiring and up-and-coming researchers complete the program: the international Early Excellence in Science Award is presented annually in the categories biology, chemistry and medicine, each with prize money of EUR 10,000. The Bayer Thrombosis Research Award, presented every two years with prize money of EUR 30,000, supports scientists in German-speaking countries whose work focuses in particular on pure and clinical research into thrombosis. The 2017 prize winner, Dr. David Seiffge, studied medicine in Heidelberg, Rennes (France) and Basel. He investigated the effect of an artificial oxygen carrier in stroke-related hypoxic brain damage in an experimental doctoral thesis developed in Professor Lothar Schilling’s laboratory in Mannheim/Heidelberg. Dr. Seiffge has worked in the Department of Neurology at Basel University Hospital under Professor Ludwig Kappos since 2011. Most of his scientific work is done in the cerebrovascular research group under Professor Engelter and Professor Lyrer, focusing on clinical research into oral anticoagulants, stroke and cerebral hemorrhage. Special funding from the University of Basel is currently enabling Dr. Seiffge to study the clinical significance of plasma levels of non-vitamin K dependent oral anticoagulants. Bayer: Science For A Better Life Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com. Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
News Article | February 2, 2016
The team studied the behaviour of an RNA structure from the microorganism Salmonella in three different scenarios: in a living cell; in an aqueous solution without additives; and in an aqueous solution with various additives that were supposed to mimic the molecules in the cells. The additives in the test tube affected the behaviour of the RNA molecules, based on the chemical composition of the additive, and on its concentration and size. Considering those results, the researchers expected the RNA molecule in the living cell - which is densely-packed with various molecules - to exhibit a different behaviour than the RNA molecule in the aqueous solution without any additives. "To our surprise, we didn't find any differences, on average, between the living cell and the diluted aqueous solution," says Junior Professor Dr Simon Ebbinghaus from the Department of Physical Chemistry II at the Ruhr-Universität Bochum, who delineates the results in the journals "Angewandte Chemie" and "Angewandte Chemie International Edition", together with RUB colleagues at the Department of Biology, at the TU Dortmund and at the Ernst Moritz Arndt University of Greifswald. "Because it contains a large number of macromolecules, the cellular environment is highly concentrated and viscous, similar to the one we simulated using artificial additives," explains Ebbinghaus. "Unlike the artificial additives, however, the cellular environment appears to modify the RNA stability only marginally." In the course of the study, the researchers analysed an RNA thermometer with a hairpin structure. At a higher temperature, the structure fuses, thus triggering a thermal shock response in microorganisms. The colour markings at the ends of the structure enabled the researchers to monitor if the hairpin unfolded under the different conditions or not. In the living cell, the stability of the RNA thermometer varied much more strongly than in the test tube. Dynamic changes in the cellular environment may affect the RNA folding continuously, the researchers suspect. The cellular environment might thus constitute a crucial factor for the regulation and modulation of various biological processes. Explore further: Early-Earth cells modeled to show how first life forms might have packaged RNA More information: Mimi Gao et al. RNA Hairpin Folding in the Crowded Cell, Angewandte Chemie International Edition (2016). DOI: 10.1002/anie.201510847
Daeschlein G.,Moritz Arndt University |
Scholz S.,Moritz Arndt University |
Arnold A.,Moritz Arndt University |
Von Podewils S.,Moritz Arndt University |
And 5 more authors.
Plasma Processes and Polymers | Year: 2012
Plasma medicine has become an emerging field in medical sciences since cold plasma has demonstrated anti-inflammatory, anti-tumor as well as antimicrobial effects. In the light of increasing resistance of many pathogens like methicillin-resistant Staphylococcus aureus (MRSA) to a multitude of antimicrobial therapies cold plasma therapy with complete different modes of action could constitute an alternative to conventional external antibiotic and antiseptic therapies. As plasma susceptibility data of human skin and wound pathogens are not available, the susceptibility of 105 typical isolates from dermatologic patients' wounds to low temperature atmospheric pressure plasma (APPJ device) and dielectric barrier discharge plasma device are tested in vitro. Plasma treatment proved to be highly effective in eradicating all (n=105) strains including Escherichia coli, Pseudomonas aeruginosa, Klebsiella group (K. pneumoniae ssp. pneumoniae, K. oxytoca), S. aureus, hemolysing Lancefield Streptococci (group A and B), Proteus group (P. mirabilis, P. vulgaris), Acinetobacter spp., Stenotrophomonas spp., Enterococcus faecalis, Candida albicans and Staphylococcus epidermidis. In conclusion, cold plasma treatment exhibited strong and rapid antimicrobial effects against clinical most relevant skin and wound pathogens in vitro. Cold plasma may constitute an effective alternative to antiseptics in the attempt to eradicate skin and wound pathogens. Three seconds of cold plasma treatment are sufficient to kill wound germs like Staphylococcus aureus including the multiresistant MRSA, Pseudomonas aeruginosa and Escherichia coli, which are redoutable germs causing substantial infection casualties worldwide. Cold plasma as first physical antisepsis in plasma medicine may become a close argument in the global fight against worldwide expanding multiresistant bacteria and related infections. Copyright © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.